Acurx Pharmaceuticals, Inc.
ACXP
$3.10
$0.3211.51%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.23M | 6.86M | 6.89M | 7.44M | 8.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.06M | 9.24M | 10.04M | 11.89M | 14.12M |
| Operating Income | -8.06M | -9.24M | -10.04M | -11.89M | -14.12M |
| Income Before Tax | -7.97M | -9.17M | -10.00M | -11.87M | -14.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.97 | -9.17 | -10.00 | -11.87 | -14.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.97M | -9.17M | -10.00M | -11.87M | -14.10M |
| EBIT | -8.06M | -9.24M | -10.04M | -11.89M | -14.12M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -5.99 | -8.54 | -10.77 | -14.09 | -17.60 |
| Normalized Basic EPS | -3.74 | -5.34 | -6.73 | -8.81 | -11.00 |
| EPS Diluted | -5.99 | -8.54 | -10.77 | -14.09 | -17.60 |
| Normalized Diluted EPS | -3.74 | -5.34 | -6.73 | -8.81 | -11.00 |
| Average Basic Shares Outstanding | 5.99M | 4.66M | 3.86M | 3.46M | 3.23M |
| Average Diluted Shares Outstanding | 5.99M | 4.66M | 3.86M | 3.46M | 3.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |